Cynata Therapeutics (ASX:CYP) reported positive efficacy data observed in preclinical studies conducted with the firm's Cymerus induced pluripotent stem cell-derived mesenchymal stem cells in models of ischaemic heart disease, according to a Monday Australian bourse filing.
The firm studied a minimally invasive method to deliver beneficial molecules from mesenchymal stem cells over an extended period, using a retrievable encapsulation device.
The treatment in a rat model of heart attack resulted in improved heart function and a reduction in harmful structural changes in the heart compared to controls treated with encapsulated placebo. It also resulted in less heart muscle thickening, smaller scar tissue, and fewer fibrous tissue buildups.
In an in vitro model of human heart tissues created and grown in a laboratory, the treatment resulted in improved survival and function compared with controls treated with placebo.
The study team submitted a manuscript describing the study to a leading peer-reviewed journal.
Its shares fell over 9% on market close on Monday, falling to its lowest point in over a year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.